HWHongxiang Wang

Hongxiang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hongxiang Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Juxiang Chen

    Department of Neurosurgery, Changhai Hospital, Naval Medical University, Shanghai, China

    3 shared publications
  • Binghong Chen

    Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

    1 shared publication
  • Chao Chen

    Department of Neurosurgery, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China

    1 shared publication
  • Chengyin Lu

    Department of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University Shanghai, China

    1 shared publication
  • Chun Liang

    Department of Cardiology, Shanghai Changzheng Hospital, Second Military Medical University Shanghai, China

    1 shared publication
  • Chunhui Ma

    Department of Orthopedics, Shanghai General Hospital of Shanghai Jiaotong University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities

    by Shuai Wang, Shizhen Liu, Yanan Zhou, Hongxiang Wang, Juxiang Chen

    BUB1 is a serine/threonine kinase and a core component of the spindle assembly checkpoint that safeguards faithful chromosome segregation during mitosis. Accumulating studies have shown that BUB1 is aberrantly expressed across multiple malignancies and contributes to tumor progression through both canonical mitotic functions and noncanonical extramitotic activities. In this review, we summarize the genetic and functional roles of BUB1 in cancer, with a focus on its involvement in chromosomal instability, aneuploidy, therapeutic resistance, and immune evasion. We discuss how BUB1 dysregulation is associated with adverse clinicopathological features and poor prognosis in several tumor types, while also highlighting context-dependent heterogeneity across cancers. Mechanistically, BUB1 contributes to malignant phenotypes by modulating mitotic checkpoint signaling, DNA damage responses, epithelial–mesenchymal transition, ferroptosis sensitivity, cancer stemness, and innate immune signaling. We further review current preclinical evidence supporting BUB1 as a therapeutic target, including the antitumor activity of small-molecule inhibitors and their synergistic potential in combination with radiotherapy, platinum agents, taxanes, and PARP inhibitors. Finally, we outline key unresolved questions, including the critical and still unresolved distinction between kinase-dependent and scaffold-dependent functions—which directly impacts inhibitor design and druggability—toxicity concerns in normal proliferating tissues, and the need for biomarker-guided patient stratification. Collectively, BUB1 represents a preclinically supported but still incompletely validated target in cancer genetics and oncogenomics.


  • Open Access

    A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma

    by Zong Miao, Lei Xu, Wei Gu, Yimin Ren, Rong Li, Shuai Zhang, Chao Chen, Hongxiang Wang, Jing Ji, Juxiang Chen


  • Open Access

    AEP-cleaved DDX3X induces alternative RNA splicing events to mediate cancer cell adaptation in harsh microenvironments

    by Wenrui Zhang, Lu Cao, Jian Yang, Shuai Zhang, Jianyi Zhao, Zhonggang Shi, Keman Liao, Haiwei Wang, Binghong Chen, Zhongrun Qian, et al.

    Oxygen and nutrient deprivation are common features of solid tumors. Although abnormal alternative splicing (AS) has been found to be an important driving force in tumor pathogenesis and progression, the regulatory mechanisms of AS that underly the adaptation of cancer cells to harsh microenvironments remain unclear. Here, we found that hypoxia- and nutrient deprivation–induced asparagine endopeptidase (AEP) specifically cleaved DDX3X in a HIF1A-dependent manner. This cleavage yields truncated carboxyl-terminal DDX3X (tDDX3X-C), which translocates and aggregates in the nucleus. Unlike intact DDX3X, nuclear tDDX3X-C complexes with an array of splicing factors and induces AS events of many pre-mRNAs; for example, enhanced exon skipping (ES) in exon 2 of the classic tumor suppressor PRDM2 leads to a frameshift mutation of PRDM2. Intriguingly, the isoform ARRB1-Δexon 13 binds to glycolytic enzymes and regulates glycolysis. By utilizing in vitro assays, glioblastoma organoids, and animal models, we revealed that AEP/tDDX3X-C promoted tumor malignancy via these isoforms. More importantly, high AEP/tDDX3X-C/ARRB1-Δexon 13 in cancerous tissues was tightly associated with poor patient prognosis. Overall, our discovery of the effect of AEP-cleaved DDX3X switching on alternative RNA splicing events identifies a mechanism in which cancer cells adapt to oxygen and nutrient shortages and provides potential diagnostic and/or therapeutic targets.


  • Open Access

    An eight-mRNA signature outperforms the lncRNA-based signature in predicting prognosis of patients with glioblastoma

    by Zhenyu Gong, Fan Hong, Hongxiang Wang, Xu Zhang, Juxiang Chen

    Background: The prognosis of the glioblastoma (GBM) is dismal. This study aims to select an optimal RNA signature for prognostic prediction of GBM patients. Methods: For the training set, the long non-coding RNA (lncRNA) and mRNA expression profiles of 151 patients were downloaded from the TCGA. Differentially expressed mRNAs (DEGs) and lncRNAs (DE-lncRNAs) were identified between good prognosis and bad prognosis patients. Optimal prognostic mRNAs and lncRNAs were selected respectively, by using univariate Cox proportional-hazards (PH) regression model and LASSO Cox-PH model. Subsequently, four prognostic scoring models were built based on expression levels or expression status of the selected prognostic lncRNAs or mRNAs, separately. Each prognostic model was applied to the training set and an independent validation set. Function analysis was used to uncover the biological roles of these prognostic DEGs between different risk groups classified by the mRNA-based signature. Results: We obtained 261 DEGs and 33 DE-lncRNAs between good prognosis and bad prognosis patients. A panel of eight mRNAs and a combination of ten lncRNAs were determined as predictive RNAs by LASSO Cox-PH model. Among the four prognostic scoring models using the eight-mRNA signature or the ten-lncRNA signature, the one based on the expression levels of the eight mRNAs showed the greatest predictive power. The DEGs between different risk groups using the eight prognostic mRNAs were functionally involved in calcium signaling pathway, neuroactive ligand-receptor interaction pathway, and Wnt signaling pathway. Conclusion: The eight-mRNA signature has greater prognostic value than the ten-lncRNA-based signature for GBM patients based on bioinformatics analysis.


    • 15 February 2016
      • Vol. 8  (2) , 1253-64

    High expression of WDR1 in primary glioblastoma is associated with poor prognosis.

    by Hanchong Xu, Yihong Chen, Cong Tan, Tao Xu, Yong Yan, Rong Qin, Qilin Huang, Chengyin Lu, Chun Liang, Yicheng Lu, et al.

    Primary glioblastoma always has a fatal outcome despite maximal therapy. Identification and validation of prognostic biomarkers and novel therapeutics will be potentially powerful to transform the care of glioblastoma patients. In this study, we constructed Affymetrix gene microarrays with 14 glioma samples to screen for genes with potential prognostic value by hieratical clustering, and 83 genes including WD-repeat containing protein 1 (WDR1) were filtered out. WDR1 is a major co-factor collaborating with cofilin in actin cytoskeletal dynamics, which may play vital role in glioma proliferation and invasion. Further, The Cancer Genome Atlas (TCGA) database was utilizedto verify the expression of WDR1 and its prognostic implicationin 528 glioblastoma specimens. Survival and correlation analyses showed WDR1 expression was highly expressed and related to the prognosis of glioblastoma and the expression of signal transducer and activator of transcription 3 (STAT3), respectively (p<0.05). Finally, WDR1 expression was detected in our large cohort containing 258 glioma patients (including 100 primary glioblastomas).And univariate and multivariate analyses confirmed that high WDR1 expression was an independent prognostic factor for a shorter progression-free survival (PFS) and overall survival (OS) in primary glioblastoma patients at our center [hazard ratio (HR)=1.844, p=0.005 and HR=2.085, p=0.001, respectively]. Together, WDR1 is significantly over-expressed in primary glioblastoma. High expression of WDR1 can independently predict unfavorable clinical outcome for primary glioblastoma patients. This study identifies a novel prognostic biomarker and a potential therapeutic target for glioblastoma.